France Hereditary Angioedema Therapeutics Market Analysis

France Hereditary Angioedema Therapeutics Market Analysis


$ 3999

France Hereditary Angioedema Therapeutics Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2030. A uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins involved in controlling the immune response. The regulatory authorities have designated numerous HAE therapies as orphan drugs as a result of this classification, pharmaceutical companies are given some incentives including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D. The increasing prevalence and diagnosis of HAE around the world have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas. Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these organisations.

ID: IN10FRRD034 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Gaurav Bhongale

Buy Now

France Hereditary Angioedema Therapeutics Market Analysis Summary

France Hereditary Angioedema Therapeutics Market is valued at around $74.8 Mn in 2022 and is projected to reach $84.67 Mn by 2030, exhibiting a CAGR of 1.56% during the forecast period 2023-2030.

An uncommon genetic condition known as hereditary angioedema (HAE) is characterised by recurrent episodes of swelling in different body areas. It is brought on by a lack or malfunction of certain proteins that control the immune response. HAE can result in sporadic swelling attacks that are potentially fatal and call for specialised care.

The regulatory authorities have designated numerous HAE therapies as orphan drugs because HAE is categorised as a rare condition. Pharmaceutical companies are given some incentives due to this classification, including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D.

The increasing prevalence and diagnosis of HAE worldwide have been driving the growth of the global market for HAE therapies. This trend offers pharmaceutical businesses the chance to increase their market share, make research and development investments, and introduce novel treatments to various geographic areas.

Hereditary angioedema therapies are being developed and produced by a number of international pharmaceutical companies (HAE). Takeda Pharmaceutical Company Limited, Inc., CSL Behring, Pharming Group NV, Ionis Pharmaceuticals, Pharvaris, Dyax Corp., Shire (now a part of Takeda), Attune Pharmaceuticals, Prometic Life Sciences Inc., KalVista Pharmaceuticals, and Biocryst are some of these businesses. They are committed to developing cutting-edge therapy strategies for HAE, including C1 esterase inhibitors, kallikrein inhibitors, and other medicines. These businesses have a significant impact on the global advancement of management and treatment choices for people with hereditary angioedema.

Market Dynamics

Market Drivers

A rare disorder with a high mortality risk is HAE. There is an unmet medical need because there haven't been any efficient and targeted treatments for HAE in the past. In an effort to enhance patient outcomes and quality of life, this motivates the development of innovative therapies to target the HAE symptoms and underlying causes. Healthcare professionals and the general public are now more aware of HAE throughout time. The need for treatments grows as HAE is better understood and diagnosed. Research advances and scientific developments in fields like genetics, immunology, and molecular biology have helped us comprehend the underlying mechanisms of HAE better. This information makes it easier to create customised treatments that target the particular pathways involved in HAE attacks. Since HAE is considered an uncommon condition, many HAE therapies are designated as orphan drugs by regulatory bodies. Pharmaceutical companies are given some incentives due to this classification, including financial advantages and prolonged exclusivity, which may promote investment in HAE R&D.

Market Development

Garadacimab subcutaneous injections given once a month significantly decreased the attack rate when compared to a placebo, according to research on the effectiveness and safety of subcutaneous administration of CSL312 (garadacimab) for the prophylactic treatment of hereditary angioedema by CSL Behring.

The investigational single injection gene therapy BMN 331 from BioMarin Pharmaceutical aims to alter the HAE disease course. According to preclinical research, BMN 331 can restore the low levels of circulating hC1-INH that induce HAE by transducing hepatocytes.

Additional encouraging interim data from a Phase 2 open-label extension (OLE) study of donidalorsen, an experimental antisense drug for the treatment of people with hereditary angioedema, were released by Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today (HAE).

The Phase 3 Clinical trial study for KalVista Pharmaceutical's KVD900, an oral plasma kallikrein inhibitor, is being conducted for the on-demand treatment of angioedema attacks in adolescent and adult patients who have hereditary angioedema type I or II attacks.

Key players

CSL Behring Shire Alexion Pharmaceuticals Pfizer BioMarin Pharmaceutical Kedrion Biopharma Grifols Novo Nordisk GlycoMimetics Breckenridge Pharmaceutical, Inc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Hereditary Angioedema Therapeutics Market

By Type

  • Type I
  • Type II

By Treatment

  • Acute
  • Prophylactic

By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 04 July 2023
Updated by: Jay Dalwadi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up